356 related articles for article (PubMed ID: 30687734)
1. Transarterial Radioembolization (TARE) Agents beyond
Bouvry C; Palard X; Edeline J; Ardisson V; Loyer P; Garin E; Lepareur N
Biomed Res Int; 2018; 2018():1435302. PubMed ID: 30687734
[TBL] [Abstract][Full Text] [Related]
2. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
El Fouly A; Ertle J; El Dorry A; Shaker MK; Dechêne A; Abdella H; Mueller S; Barakat E; Lauenstein T; Bockisch A; Gerken G; Schlaak JF
Liver Int; 2015 Feb; 35(2):627-35. PubMed ID: 25040497
[TBL] [Abstract][Full Text] [Related]
3. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
Kim DY; Han KH
Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
[TBL] [Abstract][Full Text] [Related]
5. Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease.
Fidelman N; Kerlan RK
AJR Am J Roentgenol; 2015 Oct; 205(4):742-52. PubMed ID: 26397322
[TBL] [Abstract][Full Text] [Related]
6. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
7. Transarterial Radioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models.
Mikell JK; Dewaraja YK; Owen D
Semin Radiat Oncol; 2020 Jan; 30(1):68-76. PubMed ID: 31727302
[TBL] [Abstract][Full Text] [Related]
8. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.
Kallini JR; Gabr A; Salem R; Lewandowski RJ
Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186
[TBL] [Abstract][Full Text] [Related]
9. Ytrrium-90 transarterial radioembolization in patients with gastrointestinal malignancies.
Viñal D; Minaya-Bravo A; Prieto I; Feliu J; Rodriguez-Salas N
Clin Transl Oncol; 2022 May; 24(5):796-808. PubMed ID: 35013882
[TBL] [Abstract][Full Text] [Related]
10. Yttrium 90 microspheres for the treatment of hepatocellular carcinoma.
Memon K; Lewandowski RJ; Riaz A; Salem R
Recent Results Cancer Res; 2013; 190():207-24. PubMed ID: 22941023
[TBL] [Abstract][Full Text] [Related]
11. Resin Versus Glass Microspheres for
Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
[TBL] [Abstract][Full Text] [Related]
12. Analysis of dynamic hepatobiliary contrast-enhanced MRI signal intensity after Yttrium-90 radioembolization with glass microspheres for the treatment of hepatocellular carcinoma.
Syed M; Shah J; Montazeri SA; Grajo JR; Geller B; Toskich B
Abdom Radiol (NY); 2021 May; 46(5):2182-2187. PubMed ID: 33216180
[TBL] [Abstract][Full Text] [Related]
13. Radioembolization for the treatment of hepatocellular carcinoma.
Kim HC
Clin Mol Hepatol; 2017 Jun; 23(2):109-114. PubMed ID: 28494530
[TBL] [Abstract][Full Text] [Related]
14. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization.
Hardy-Abeloos C; Lazarev S; Ru M; Kim E; Fischman A; Moshier E; Rosenzweig K; Buckstein M
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):968-976. PubMed ID: 31536781
[TBL] [Abstract][Full Text] [Related]
16. Preliminary experience in radionuclide therapy of hepatocellular carcinoma using hepatic intra-arterial radio-conjugates.
Keng GH; Sundram FX; Yu SW; Somanesan S; Premaraj J; Oon CJ; Kwok R; Htoo MM
Ann Acad Med Singap; 2002 May; 31(3):382-6. PubMed ID: 12061301
[TBL] [Abstract][Full Text] [Related]
17. Evolution of Radioembolization in Treatment of Hepatocellular Carcinoma: A Pictorial Review.
Miller FH; Lopes Vendrami C; Gabr A; Horowitz JM; Kelahan LC; Riaz A; Salem R; Lewandowski RJ
Radiographics; 2021 Oct; 41(6):1802-1818. PubMed ID: 34559587
[TBL] [Abstract][Full Text] [Related]
18. Yttrium-90 Radioembolization for Hepatocellular Carcinoma.
Hickey RM; Lewandowski RJ; Salem R
Semin Nucl Med; 2016 Mar; 46(2):105-8. PubMed ID: 26897714
[TBL] [Abstract][Full Text] [Related]
19. Y90 Radioembolization Dosimetry: Concepts for the Interventional Radiologist.
Toskich BB; Liu DM
Tech Vasc Interv Radiol; 2019 Jun; 22(2):100-111. PubMed ID: 31079706
[TBL] [Abstract][Full Text] [Related]
20. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.
Walton M; Wade R; Claxton L; Sharif-Hurst S; Harden M; Patel J; Rowe I; Hodgson R; Eastwood A
Health Technol Assess; 2020 Sep; 24(48):1-264. PubMed ID: 33001024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
